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Introduction
The mechanisms underlying the normal repair process, cell migration and proliferation, and extracellular matrix deposition and remodelling, have been extensively studied [1] [2] [3] . Cellular responses to inflammatory mediators, growth factors, cytokines, and to mechanical forces must be appropriate and precise in order to obtain optimum healing of a cutaneous wound. However, even during the normal process of wound healing complications can occur, including infection, thrombosis, and ischemia. [4, 5] . More importantly, the orderly progression of the healing process is impaired in chronic wounds, including those due to diabetes.
Impaired wound healing is a major concern for diabetic patients because their wounds do not heal properly and are a source of major suffering and cost. Only two-thirds of diabetic foot ulcers eventually heal and up to 28% may result in amputation [6] . The pathogenesis of diabetic foot ulcers is complex and it is well recognized that a number of contributory factors working together ultimately lead to impaired healing. Several intrinsic factors, such as peripheral neuropathy, foot deformity, peripheral vascular disease and peripheral oedema have been identified as the commonest factors responsible of impaired healing after trauma. In addition, extrinsic factors, such as wound infection, callus formation, and excessive pressure to the site, further aggravate the healing process [7] .
Recent studies suggest that nerves play a central role in tissue homeostasis and can orchestrate complex reparative as well as destructive processes. First, an intact nociceptor system of primary afferent sensory nerves is important for the initiation of the inflammatory process and successful tissue repair [8] . Apart from the loss of pain perception, which is a key factor in the development 5 of neuropathic foot ulcers, loss of autonomic function and small fibre neuropathy can result in impaired neurogenic control of local microcirculatory blood flow, impaired fluid homeostasis, diminished energy metabolism, oxygen delivery, and inflammatory responses. These processes could render the feet of diabetic patients with neuropathy more susceptible to tissue damage and infection [9] .
Given the complexity of the pathogenesis of diabetic foot ulcers, many different interventions have been proposed to accelerate the healing process, but few have been subjected to formal evaluation. Despite the relatively large number of studies of growth factors like PDGF (becaplermin), EGF, basic FGF and other agents modulating aspects of wound physiology, there is currently little evidence to suggest that any of the reported interventions should be adopted in routine practice. Diabetic foot ulcer management is based on the simple principles of eliminating infection, debridement, cleansing and the use of dressings to maintain a moist wound bed, and lastly, becaplermin is the only promoting agent approved for use of those ulcers resistant to simpler interventions [6] .
Based in studies carried out in vitro and in experimental animal models, we are proposing a new strategy for the promotion of impaired wound healing, the use of adenosine receptor agonists.
We will summarized the biology of adenosine and review its actions on different tissues and cells implicated in the healing of cutaneous wounds, as well as its effect on experimental wounds in animals.
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Purine metabolism and biology
Adenosine is a ubiquitous purine nucleoside produced by stepwise dephosphorylation of ATP by the coordinated action of ecto-apyrase (CD39) and ecto-5'-nucleotidase (CD73) (Figure 1 activation stimulates an increase in intracellular cAMP. In addition, they couple to mitogenactivated protein kinases (MAPK), which may give them a role in cell growth, survival, death and differentiation [12] . The affinity of selected agonists at the different adenosine receptor subtypes is summarized on Table 1 .
Extracellular actions of purines in non-neuronal cells, including fast signalling roles in exocrine and endocrine secretion, platelet aggregation, cardiovascular effects and kidney function, have been known for a long time. More recently, slow purinergic signalling has been implicated in embryological development, wound healing, restenosis, atherosclerosis, ischaemia, cell turnover of epithelial cells in skin and visceral organs, inflammation, neuroprotection and cancer [13, 14] .
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More interestingly, purines and pyrimidines have major roles in the activities of neurons. This includes nociceptive mechanosensory transduction, as well as acting as a cotransmitter and neuromodulator in most, if not all, nerve types in the peripheral and central nervous systems [13] .
This raises the innovative hypothesis that diabetic patients suffering from peripheral neuropathy will have altered purinergic neurotransmission.
Could adenosine play a role in normal wound healing?
Under basal conditions, the extracellular adenosine concentration is rather constant (30-300 nM), and held in tight check by the equilibrium between adenosine production/release into the extracellular space and adenosine uptake by cells or catabolism to inosine ( Figure 1 been established yet. In this regard, streptozotocin-induced diabetes in rats altered adenosine receptors expression in liver, heart and kidney and administration of insulin returned their levels to normality [22]
Adenosine in inflammation
Hemostasis and inflammation constitute the first phase of tissue repair. The formation of a blood clot re-establishes tissue hemostasis and provides a provisional matrix for cell migration.
Released cellular mediators initiate inflammatory leukocyte recruitment necessary for removing necrotic tissue and preventing infection [1] . In addition, inflammatory cells release a variety of cytokines and chemokines that play an important role in the evolution of granulation tissue through stimulation of fibroblasts and epithelial cells [4] . However, despite its importance, persistent or exaggerated inflammation could be detrimental for the healing process in some pathological settings. In this respect, the concept that diabetes is a low-level chronic inflammatory disease is commonly accepted [23, 24] .
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It has been firmly established that adenosine modulates the production of both inflammatory and anti-inflammatory cytokines including TNF, IL-10, and IL-12 [16, 43] . The anti-inflammatory effect of adenosine could be beneficial since some reports depict a deleterious effect of TNF in wound healing [44] 
Adenosine in tissue formation
Driven by growth factors synthesized by local and migratory cells, fibroblasts migrate on the provisional fibrin scaffold into the wound where they proliferate and construct a more robust collagen rich extracellular matrix. Wound fibroblasts acquire a distinctive contractile and secretory phenotype, known as myofibroblasts, responsible for wound contraction, a very important event in full thickness wounds. In response to many of the same growth factors, epidermal cells migrate from the edge of the wound over the surface of the injured area and proliferate until there is complete wound closure [1, 5] . A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 normal human epidermal keratinocytes cultured in the absence or presence of exogenous epidermal growth factor [46] .Similarly, the result of adenosine receptor activation in fibroblast proliferation remains unclear [47, 48] . Studies in our laboratory indicated that adenosine A 2 receptor occupancy, both A 2A and A 2B , contributes to enhanced fibroblast and endothelial cell migration. [49] .
We have recently reported that activation of adenosine A 2A receptors promotes collagen synthesis by human dermal fibroblasts and that blockade or deletion of this receptor in mice protects against bleomycin-induced dermal fibrosis, a murine model of scleroderma [17] . These data confirm a fibrogenic role for adenosine in the skin [50] . We also found an increased number of myofibroblasts associated with elevated skin adenosine concentration, a phenomenon that was prevented by pharmacological blockade of A 2A receptors [51] . Although these results are consistent with a fibrogenic role for adenosine A2A receptor activation, a possible role for adenosine A2B receptors cannot be ruled out, since the concentration of the antagonist ZM-12 241385 used in these studies is high enough to also antagonize rodent A2B receptors [52] .
Wound healing models have not been studied in ADA-deficient mice.
Adenosine in neovascularization
Revascularization of the wound bed is essential to supply oxygen, nutrients, and inflammatory cells to the newly growing tissue. Two mechanisms contribute to the development of new vessels in the adult: angiogenesis, the formation of new vessels from pre-existing ones; and vasculogenesis, the initial series of events in vascular growth in which endothelial cell precursors (angioblasts) differentiate in situ and assemble into solid endothelial cords [53] This multistep process is highly regulated by a variety of soluble angiogenic growth factors, proteolytic enzymes, which allow endothelial cell detachment and extracellular matrix invasion, and a close interaction between adhesive proteins of the extracellular matrix and their integrin receptors [54, 55] . Among the growth factors implicated in the angiogenic process, bFGF and vascular endothelial growth factor (VEGF) are known to be potent angiogenic molecules that induce the growth of new blood vessels during wound healing and embryonic development. [56, 57] .
Diabetic patients frequently suffer from macro and microvascular complications characterized by an early dysfunction of vascular endothelium that could further aggravate their impaired healing.
Many studies have shown that the administration of adenosine or adenosine agonists as well as the upregulation of endogenous adenosine can increase the expression of vascular endothelial growth factor (VEGF) in a variety of different cells studied in vitro [58] [59] [60] [61] [62] and after intravenous infusion of adenosine in humans [63] . Adenosine A 2A receptors activation stimulates macrophage 13 production of VEGF as well [60] , meanwhile adenosine A 2B receptors induce VEGF release by retinal endothelial cells [59, 61] .
The elevated expression of VEGF might account for the angiogenic effects of adenosine;
however, it is more likely that adenosine also stimulates angiogenesis via other secondary angiogenic and antiangiogenic mediators or by way of an intracellular action [64] . Thus, the adenosine analog NECA also increased the expression of the proangiogenic factors insulin-like agonists can promote in vitro angiogenesis by inhibiting endothelial secretion of the antiangiogenic factor thrombospondin-1 [66] .
Adenosine in remodeling
The reparative process culminates with the remodelling of the newly formed granulation tissue in order to restore complete functionality. During this extended phase, the provisional extracellular matrix rich in type 3 collagen is degraded by serine proteases and metalloproteases and sequentially substituted for the definitive matrix rich in type 1 collagen [1] Activation of plasminogen plays a role in proteolytic degradation of extracellular matrices in tissue remodelling events and it is required for normal repair of skin wounds in mice [67] . Earlier reports showed that the non selective adenosine receptor agonist NECA increased plasminogen A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 activator release in rabbit alveolar macrophages due to intracellular elevations of cAMP [68] .
Similarly, cAMP elevating agents increased the acute release of tissue plasminogen activator in human umbilical endothelial cells [69, 70] and intraarterial infusions of ATP, an adenosine precursor, to healthy volunteers induce tPA release [71] .
Adenosine agonist promotion of wound healing in animal models
Much of the knowledge of the normal healing process of cutaneous wounds and the mediators involved has evolved from information derived from experimental wounds in animals, especially genetically modified mice. Unfortunately, a valid model of chronic wounds in animals has not yet been developed. From the in vitro experiment data it is difficult to predict which adenosine agonists, if any, will be useful for promoting impaired wound healing in humans.
There are few reports of the use of adenosine agonists for the enhancement of wound healing. We have demonstrated pharmacologically and by the use of mice lacking A 2A receptors that topical application of adenosine A 2A receptor agonists accelerate healing of dermal wounds in both healthy animals and in streptozotocin-induced diabetic rats with impaired wound healing [18, 49, 72] . Histological analysis showed faster re-epithelialization and increased matrix deposition, fibroblast density and vascularity in the granulation tissue of the agonist treated wounds as soon as 3 days after injury [18] . In a model of pressure ulcer formation as a result of recurrent ischemia-reperfusion of the skin, an adenosine A 2A receptor agonist infused via osmotic minipumps reduced leukocyte infiltration and protected from ischemia/reperfusion injury in skin [73] . No signs of fibrosis were described in these experimental animal models.
Page 15 of 32
A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 antagonist, but the contribution of other receptors was not determined [45] . Topical application of the adenosine A 1 receptor agonist, N(6)-Cyclopentyladenosine (CPA), also promoted healing of incisional and excisional wounds on the dorsum of both diabetic (db/db) and normal (db/+) mice, although the concentration used was above the selectivity threshold and the participation of other receptors cannot be ruled out. Interestengly, hair growth along the wound margin was enhanced in agonist-treated mice, an effect that has not been described for adenosine A 2A agonists [48] .
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As inferred from the in vitro studies previously described, many factors contribute to the effect of adenosine receptor activation in promoting wound healing. The synergistic interaction between
Toll-like receptor and adenosine A 2A receptor signaling switches macrophages towards an angiogenic phenotype [60, 75] , and plays a role in an excisional wound healing model. Mice 
Conclusion
Nowadays there is a high awareness of the problem that diabetic foot ulcers represent in terms of costs and quality of life for those suffering them. Studies to better understand the normal healing process and the pathology of impaired healing have been extremely useful to improve wound 17 management and care. Randomized controlled trials have shown that topical application of becaplermin gel is effective in increasing healing rates for diabetic neuropathic foot ulcers with adequate blood supply. However, this efficacy has not translated to positive clinical experience, and the drug is not widely used. Moreover, it is an expensive medication of relative short storage stability and an increased risk of mortality secondary to malignancy was observed in patients.
Adenosine receptor agonists represent an attractive and novel alternative to growth factors for promotion of diabetic foot chronic ulcers. They are small synthetic molecules of longer stability and lower cost than growth factors. Given the complexity of the pathogenesis of foot ulcers and the differential adenosine receptor expression in the cells involved in the impaired tissue repair process, it is difficult to predict which agonists, selective or not, could be most useful. To add more complexity, all four receptor adenosine subtypes are G protein-coupled receptors, but also exert cAMP-independent actions. In addition, they couple to mitogen-activated protein kinases by mechanisms that appear to differ substantially, both between receptor subtypes in the same cell type and between the same receptor in different cell types. From our studies, selective adenosine A 2A receptor agonists present the advantages of reducing inflammation and increasing vascularization and extracellular matrix deposition. Nevertheless, the fibrogenic potential and increased risk of infection should also be monitorized. Other important factors to be considered are the pharmaceutical formulation and the pharmacokinetics of the agonist used, in order to minimize its systemic effects. As any new strategy in the management of chronic wounds, the use of adenosine agonists has to be evaluated and validated before taking it into practice. M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 A c c e p t e d M a n u s c r i p t 
